Iris Pharma equips itself with two new "high-end" evaluation instruments

As one of the rare CROs in the world to benefit from these instruments, Iris Pharma improves its expertise in preclinical ophthalmic research

Iris Pharma, the internationally renowned contract research organisation (CRO) specialising in preclinical and clinical ophthalmic research, has announced that it has just expanded its range of instruments by acquiring a HRA-OCT Spectralis® and a Luminex® Lx200 IS analysis system.

 As one of the rare CROs in the world to benefit from these two instruments, Iris Pharma further improves its expertise in preclinical ophthalmic research and offers its customers high precision evaluation tools to monitor treatments during studies.

 According to Philippe Margaron, Director of the preclinical department "to be able to observe and measure the slightest anatomical or biochemical change and the development of the disease in an animal model in complete confidence, could greatly influence the decisions made with regards a new treatment." Furthermore, the advantage of the OCT Spectralis® is that it establishes a continuity between preclinical and clinical research because it can be used with both humans and animals: "animal studies imitate a patient's treatment and give our customers access to the same techniques as those available to doctors."

 Imaging and research benefits

The HRA-OCT Spectralis® can be used to monitor the treated retina areas and their development with great precision. The multi-modal imaging technique offers a detailed view of the structure and an overview of the complaint in real time, and consequently plays a major role in detecting retinal involvement and pigment epithelium.

The Luminex Lx200 system is used to perform biochemical quantifications and multiple simultaneous doses from low-volume samples. It is already allowing Iris Pharma to produce cytokines doses of in its inflammation models and particularly in the EIU (Endotoxin-induced uveitis) model.

Imaging and ethics

Non-invasive imaging helps in the application of the 3 Rs (Replacement, Refinement, Reduction). It makes it possible to make in vivo cuts and assess the disease and its development during the animal's lifetime and, by increasing the number of combined measurement markers, can help to increase the information obtained from a single individual. Furthermore, the reliability of such machines provides better data limiting the need to resort to complementary or repeat studies.

En savoir plus : www.iris-pharma.com